Physicians' Academy for Cardiovascular Education
A study shows that elevated Lp(a) is independently associated with accelerated progression of low-attenuation plaque in patients with advanced multivessel CAD on guideline-directed preventive therapies.
Although alirocumab reduced LDL-c in patients with or without a history of HF, alirocumab reduced MACE only in patients without HF and not in patients with a history of HF, in an analysis of ODYSSEY OUTCOMES.
A meta-analysis of three observational cohort studies shows that prolonged TV viewing is associated with a higher risk of venous thrombo-embolism (VTE) compared to participants that never or seldom watched TV.
A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.
This study investigated the association between multiple indices of adiposity (both novel and established indices) and the risk of incident HF in a community-based cohort.
A network meta-analysis of 15 RCTs shows that a guided selection of P2Y12 inhibiting therapy using platelet function or genetic testing is the only strategy associated with a reduction of ischemic events without a trade-off in bleeding in patients with ACS.
Andexanet alfa specifically binds and sequesters factor Xa inhibitors. A study investigated the efficacy and safety of andexanet alfa in patients on edoxaban with acute major bleeding.
There was no difference of icosapent ethyl efficacy among statin agents and statin categories (lipophilic vs. lipophobic statins) in an exploratory analysis of the REDUCE-IT trial.
A study shows that epicardial adipose tissue volume is significantly associated with all-cause mortality and HF hospitalization in patients with HFmrEF and HFpEF.
Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a high thrombotic risk, according to prof. Verheugt.
The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the NOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.
A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.
